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Abstract Chemical compounds that interfere with an
enzymatic function of kinases are useful for gaining insight
into the complicated biochemical processes in mammalian
cells. Cyclin-dependent kinases (CDK) play an essential
role in the control of the cell cycle and/or proliferation.
These kinases as well as their regulators are frequently
deregulated in diVerent human tumors. Aberrations in CDK
activity have also been observed in viral infections,
Alzheimer’s, Parkinson’s diseases, ischemia and some
proliferative disorders. This led to an intensive search for
small-molecule CDK inhibitors not only for research
purposes, but also for therapeutic applications. Here, we
discuss seventeen CDK inhibitors and their use in cancer
research or therapy. This review should help researchers to
decide which inhibitor is best suited for the speciWc purpose
of their research. For this purpose, the targets, commercial
availability and IC50 values are provided for each inhibitor.
The review will also provide an overview of the clinical
studies performed with some of these inhibitors.
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Introduction
Protein kinases are a large family of enzymes catalyzing
protein phosphorylation. The phosphorylation results in a
change in function of proteins such as their location, inter-
action with other proteins or enzymatic activity. The human
genome contains more than 500 protein kinase genes. Pro-
tein phosphorylation plays a central role in the regulation of
cell proliferation, diVerentiation and apoptosis. Therefore,
deregulation of kinase activity can result in striking
changes in these processes. Particularly, deregulated
kinases are often found to be oncogenic and can be central
for the survival of cancer cells (Hunter and Cooper 1985).
Moreover, the phosphorylation of some proteins, such as
ErbB2 (Cicenas et al. 2006; Cicenas 2007; DiGiovanna
et al. 2005), EGFR (Cicenas 2007; Kanematsu et al. 2003),
Erk (Milde-Langosch et al. 2005; Bergqvist et al. 2006;
Svensson et al. 2005), SchA (Cicenas et al. 2010), p21Cip1
(Xia et al. 2004), p27Kip1 (Clarke 2003), Akt (Cicenas
et al. 2004, 2005; Cicenas 2008) and retinoblastoma protein
(Rb) (Derenzini et al. 2007), is associated with prognosis in
cancers.
Cyclin-dependent kinases (CDKs) are protein kinases
involved in important cellular processes, such as cell cycle
or transcription regulation. Human genome contains 21
genes encoding CDKs and Wve genes encoding more dis-
tant protein kinases entitled CDK-like (CDKL) kinases.
Recently, the new nomenclature for the CDKs had been
proposed (Malumbres et al. 2009). The roles of “classical”
11 CDK proteins have been investigated to a diVerent
extent. DiVerent CDKs are responsible for the activation of
the cell cycle of quiescent cells as well as for the progres-
sion of the cell cycle from G1 to mitosis. Each of the CDKs
controls a speciWc checkpoint of the cell cycle. CDKs are
activated by the binding to the cyclins and thus forming
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speciWc complexes. Cdk4–CyclinD, Cdk6–CyclinD and
Cdk2–CyclinE complexes regulate the G0–G1 transition
and the early phases of G1 through phosphorylation of the
Rb. Cdk2–CyclinE complexes are also involved in the G1–
S transition. Cdk2 can also associate with CyclinA through-
out the progression of S phase. Cdk1–CyclinA complex
participates in the S–G2 and Cdk1–CyclinB G2–M
(Malumbres and Barbacid 2005). Cdk3 seems to also par-
ticipate in Rb phosphorylation. It is highly related to Cdk2
and Cdk1 and interacts with CyclinE and CyclinA. Cdk5 is
activated by p35 and p39 proteins that are not cyclins and
are typically expressed in brain. Cdk5 mostly acts in neural
cells and is involved in the regulation of cell survival, tran-
scription, migration and membrane transport (Dhariwala
and Rajadhyaksha 2008). Cdk7 is a component of the Cdk-
activating kinase (CAK), which acts upstream of cell-cycle
CDKs. It is also a component of the general transcription
factor TFIIH and is involved in transcription (Fisher 2005).
Cdk8 binds to CyclinC and Cdk9 binds to CyclinT, and
they are also involved in the regulation of transcription
(Malumbres and Barbacid 2005). No cyclin partner for
Cdk10 has been identiWed so far; however, this kinase
seems to be involved in regulating the G2–M phase by inhi-
bition of Ets2 transactivation (Kasten and Giordano 2001).
Cdk11 binds to CyclinL and is involved in mRNA splicing
(Loyer et al. 2008). It can also interact with CyclinD and
repress proliferation (Duan et al. 2010).
Most of the CDKs have been implicated in human can-
cers. CDK1 had been shown to have a diagnostic value in
esophageal (Hansel et al. 2005) and breast cancers (Kim
et al. 2008; Nakayama et al. 2009). CDK2 expression or
activity has been used for the prognosis of breast (Kim
et al. 2008), ovarian (Marone et al. 1998) and oral (Mihara
et al. 2001) cancers. Aberrant expression of CDK4 has been
implicated in ovarian (Kusume et al. 1999), urinary bladder
(Simon et al. 2002), endometrial (Semczuk et al. 2004) and
oral (Poomsawat et al. 2010) cancers. CDK5 has been
shown to be involved in lung cancer (Choi et al. 2009; Liu
et al. 2010). The expression of CDK 6 is also altered in oral
cancer (Poomsawat et al. 2010). CDK7 polymorphisms
have been shown to have an eVect on breast cancer (Jeon
et al. 2010).
Aberrations in CDK expression, activity and regulation
have also been found in viral infections, neurodegenerative
disorders, proliferative diseases, etc. That led to an inten-
sive hunt for small-molecule CDK inhibitors for the thera-
peutic purposes. All CDK inhibitors developed to date can
be subdivided into two main groups: broad-range inhibitors
(such as Xavopiridol, olomoucine, roscovitine, kenpaul-
lone, SNS-032, AT7519, AG-024322, (S)-Roscovitine and
R547) and speciWc inhibitors (such as fascaplysin, ryuvi-
dine, purvalanol A, NU2058, BML-259, SU 9516, PD
0332991 and P-276–00). The aim of this review is to
discuss the properties as well as the use of these inhibitors
in cancer research and therapy in more detail.
Broad-range inhibitors
Flavopiridol (Fig. 1) (also L-868275, HMR-1275, Alvoci-
dib or NSC-649890) is a broad-range CDK inhibitor. It
inhibits CDK1, CDK2, CDK4 and CDK7 at IC50 value
range of 0.04–0.4 M (Losiewicz et al. 1994; Carlson et al.
1996). It was Wrst discovered as epidermal growth factor
receptor (EGFR) inhibitor, which inhibits at IC50 value of
21 M. Later, it was shown that Xavopiridol could inhibit
the growth of breast and lung cancer cell lines (Kaur et al.
1992) and prostate, head and neck cancer and leukemia
xenografts (Drees et al. 1997; Patel et al. 1998; Arguello
et al. 1998). Since it did so at much lower concentrations
than those needed for the inhibition of the EGFR, new tar-
gets were investigated and its eVect on CDKs was found.
Flavopiridol is a commercially available inhibitor
broadly used in the research. It is also the Wrst CDK inhibi-
tor used in human clinical trials. Several phase I clinical
trials showed that Xavopiridol as single agent has an
antitumor eVect in patients with renal, prostate and colon
cancer, metastatic gastric cancer and non-Hodgkin’s lym-
phoma (Senderowicz et al. 1998; Tan et al. 2002; Thomas
et al. 2002; Whitlock et al. 2005). Secretory diarrhea, neu-
tropenia, nausea, vomiting and proinXammatory syndrome
were reported as main drug adverse eVects (DAE). Another
phase I clinical study of sequential paclitaxel and Xavopir-
idol showed clinical activity in patients with esophagus,
lung and prostate cancer including patients who had not
Fig. 1 Flavopiridol, Olomoucine and Roscovitine
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responded to paclitaxel alone (Schwartz et al. 2002). The
combination of Xavopiridol and docetaxel has been shown
to be quite promising in several phase I clinical studies
(Fornier et al. 2007; El-Rayes et al. 2006; Tan et al. 2004).
The combinations of Xavopiridol with gemcitabine and iri-
notecan (Fekrazad et al. 2010), vorinostat (Dickson et al.
2010), oxaliplatin and Xuorouracil/leucovorin (Rathkopf
et al. 2009), paclitaxel and carboplatin (George et al. 2008),
cisplatin and carboplatin (Bible et al. 2005) and irinotecan
(Shah et al. 2005) were also assessed in various solid
tumors in phase I clinical trials. In leukemias, Xavopiridol
both as single agent (Phelps et al. 2009; Blum et al. 2010)
and in combinations with 1-beta-D-arabinofuranosylcyto-
sine and mitoxantrone (Karp et al. 2005) and cytosine ara-
binoside and mitoxantrone (Karp et al. 2011) showed a
promise in phase I clinical trials.
Phase II clinical trials involving Xavopiridol have also
been carried out. Flavopiridol, however, did not have a
desired eVect in advanced gastric carcinoma (Schwartz
et al. 2001), non-small-cell lung cancer (Shapiro et al.
2001), advanced colorectal cancer (Aklilu et al. 2003),
androgen-independent prostate cancer (Liu et al. 2004),
melanoma (Burdette-Radoux et al. 2004), endometrial car-
cinoma (Grendys et al. 2005) and advanced soft tissue sar-
coma (Morris et al. 2006). It did have a modest eVect in
mantle cell lymphoma (Kouroukis et al. 2003) and
advanced renal cell carcinoma (Van Veldhuizen et al.
2005). Yet in another phase II clinical trial, Xavopiridol
achieved signiWcant clinical activity in patients with
relapsed chronic lymphocytic leukemia (Lin et al. 2009). A
phase II study of Xavopiridol in combination with docetaxel
in pancreatic cancer was also disappointing (Carvajal et al.
2009).
Olomoucine (Fig. 1) is another broad-range CDK inhibi-
tor. It inhibits CDK1 (IC50 = 7 M), CDK2 (IC50 = 7 M)
and CDK5 (IC50 = 3 M). It can also inhibit ERK1 kinase
at higher concentrations (IC50 = 25 M). Olomoucine is
also a commercially available inhibitor and was Wrst purine
CDK inhibitor discovered. Olomoucine has never been
used in any clinical trials, since the preference was given to
its derivative—roscovitine.
Roscovitine (Fig. 1) (also CY-202, (R)-Roscovitine, Seli-
ciclib) is also a broad-range purine inhibitor, which inhibits
CDK1, CDK2, CDK5 and CDK7 (IC50 » 0.5–0.2 M) but is
a poor inhibitor for CDK 4 and CDK 6 (IC50 > 100 M). It is
also commercially available CDK inhibitor broadly used in
the research. Oddly, in a scientiWc literature, it is frequently
referred to as a selective CDK5 inhibitor, despite the fact that
it inhibits at least other 3 CDKs. A phase I clinical trial with
roscovitine showed no objective tumor responses, but disease
stabilization was observed in eight patients (Benson et al.
2007). Main DAEs included fatigue, skin rash, hyponatremia
and hypokalemia. Emesis and reversible abnormal liver
function were also observed. In another phase I clinical trial,
one patient with hepatocellular carcinoma showed partial
response and six patients achieved tumor (two patients with
NSCLC, one with parotid cylindroma, one with corticosur-
renaloma, one with thymic carcinoma and one with adeno-
carcinoma of unknown primary) (Le Tourneau et al. 2010).
DAEs included nausea, vomiting, asthenia and hypokalemia.
Roscovitine is presently under investigation in several phase
II clinical trials in leukemias as monotheraphy and in combi-
nation trials against NCLC (with gemcitabine/cisplatin or
docetaxel) and metastatic breast cancer (with capecitabine)
(Fischer and Gianella-Borradori 2005).
Kenpaullone (Fig. 2) (also NSC 664704, 9-Bromopaul-
lone), another commercially available broad-range CDK
inhibitor, inhibits CDK1 (IC50 = 0.4 M), CDK2
(IC50 = 0.7 M) and CDK5 (IC50 = 0.9 M). It is much less
potent toward CDK4 (IC50 > 100 M). It also inhibits
GSK3 (IC50 = 0.23 M). Kenpaullone was found as an in
vitro antiproliferative agent in the NCI’s anticancer drug
screen panel, and molecular modeling studies have shown
that it binds to the ATP-binding pocket of CDK2 similar to
other CDK2 inhibitors. Although it is a commercially avail-
able inhibitor vastly used in research, it had not entered
clinical trials so far.
SNS-032 (also BMS-387032) (Fig. 2) is a broad-range
inhibitor, which inhibits CDK9 (IC50 = 0.004 M), CDK2
(IC50 = 0.038 M) and CDK7 (IC50 = 0.062 M). It can
inhibit other CDKs at higher concentration (IC50 > 0.3 M),
but at that concentration, it also inhibits GSK3 kinase.
SNS-032 was initially synthesized by Bristol-Myers Squibb
Pharmaceutical Research Institute in an attempt to produce
a selective inhibitor of CDK2. It was named BMS-387032
at the time. Two phase I clinical trials were carried out for
Fig. 2 Kenpaulollone, SNS-032 and ATZ519
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metastatic refractory solid tumors and one in lymphoma.
All those trials showed that this drug was well tolerated by
the patients. Later, already under SNS-032 name, the phase
I clinical trial was performed with 21 patients. Patients with
metastatic solid tumors or refractory lymphoma were
treated with an intravenously administered SNS-032 in a
dose-escalation manner. Drug was well tolerated, DAEs
being fatigue and nausea. The best clinical response was
stable disease in 3 (15%) patients (Heath et al. 2008).
Another phase I trial was performed in 19 patients with
advanced chronic lymphocytic leukemia and multiple
myeloma (Tong et al. 2010). Major toxicity in that case was
myelosuppression. One patient with a chronic lymphocytic
leukemia had more than 50% reduction in measurable dis-
ease, and two patients with multiple myeloma had stable
disease and one had normalization of spleen size.
AT7519 (Fig. 2) is a broad-range CDK inhibitor, which
inhibits CDK1 (IC50 = 0.21 M), CDK2 (IC50 = 0.047 M),
CDK4 (IC50 = 0.1 M), CDK5 (IC50 = 0.13 M), CDK6
(IC50 = 0.17 M) and CDK9 (IC50 · 0.01 M). This com-
pound had lower potency against other CDKs tested
(CDK3 and CDK7) and was inactive against all of the non-
CDK kinases tested with the exception of GSK3
(IC50 = 0.089 M). Phase I clinical trial was carried out in
28 patients with refractory solid tumors (Mahadevan et al.
2011). Electrocardiogram showed a dose-dependent
increase in QTc. Other adverse eVects included fatigue and
mucositis. Four patients showed stable disease for more
than 6 months and one had an extended partial response. In
2010, Astex Therapeutics and the Multiple Myeloma
Research Consortium announced the initiation of a phase II
clinical trial of the AT7519 to treat patients with relapsed or
refractory multiple myeloma.
AG-024322 (Fig. 3) is a broad-range inhibitor, which
inhibits CDK1, CDK2 and CDK4 (IC50 = 0.1–0.3 M).
AG-024322 was synthesized by PWzer Global Research and
Development. This inhibitor had been entered into phase I
clinical trials, which, however, had been terminated due to
the inability of the compound to eVectively discriminate
from other treatment modalities.
(S)-Roscovitine (Fig. 3) is an inhibitor, which potently
inhibits CDK1 (IC50 = 0.55 M), CDK5 (IC50 = 0.35 M)
and CDK9 (IC50 = 0.9 M). It has been neglected as a ther-
apeutical agent in favor of its isomer (R)-Roscovitine, men-
tioned above.
R547 (also Ro-4584820) (Fig. 3) is an inhibitor selective
for CDK1 (IC50 = 0.001 M), CDK2 (IC50 = 0.003 M)
and CDK4 (IC50 = 0.001 M). In 2006, HoVmann-La
Roche initiated a phase I study of R547 against locally
advanced or metastatic solid tumors; however, results had
not been published to date. On the other hand, the expres-
sion in patient blood samples of eight genes (FLJ44342,
CD86, EGR1, MKI67, CCNB1, JUN, HEXIM1 and
PFAAP5) was selected as dose-responsive pharmacody-
namic parameter for phase II clinical trials (Berkofsky-
Fessler et al. 2009).
Selective inhibitors
Fascaplysin (Fig. 4) is an inhibitor selective for CDK4
(IC50 = 0.35 M) and CDK6 (IC50 = 3.4 M) and not selec-
tive for the other CDKs or other kinases. It was originally iso-
lated as a compound showing antimicrobial activity from the
sponge Fascaplysinopsis sp. (Roll et al. 1988). It is a commer-
cially available compound, broadly used for the research pur-
poses; however, it has never been entered into clinical trials.
Ryuvidine (Fig. 4) is an inhibitor selective for CDK4
(IC50 = 6.0 M) and displays >33-fold selectivity over
Fig. 3 AG-024322, (S)-Roscovitine, R547
Fig. 4 NU2058, Fascaplysin and Ryuvidine
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CDK2 (IC50 > 200 M). Despite the fact that this inhibitor
is commercially available, it has not been used widely in
the research, nor had it ever entered the clinical trials. How-
ever, given its selectivity toward CDK4, as well as cytotox-
icity against various cancer cells (IC50 = 0.61, 1.08, 0.30
and 1.21 mg/ml against A 549, Col 1, HL-60 and HepG2
tumor cells, respectively) (Ryu et al. 2000), it seems to be
quite potent tool for cancer research.
Purvalanol A (Fig. 5) is an inhibitor selective for CDK2
(IC50 = 4–70 nM) and CDK5 (IC50 = 75 nM), but less
selective toward CDK4 (IC50 = 850 nM). This inhibitor
was identiWed by combinatorial chemistry approach struc-
ture–activity relationship (SAR). It is also a commercially
available inhibitor, quite widely used in cancer research
(Villerbu et al. 2002). However, purvalanol A has never
been entered into clinical trials.
NU2058 (Fig. 4) is an inhibitor selective for CDK2
(IC50 = 17 M) and CDK1 (IC50 = 26 M). NU2058 is a
competitive inhibitor that binds in the ATP-binding pocket
in a diVerent orientation from other purine-based inhibitors,
such as olomoucine and roscovitine (Arris et al. 2000). So
far, only preclinical studies had been performed, showing
the potential of the compound against several cancer cell
lines. This inhibitor had not been entered into clinical trials
yet. It is also commercially available.
BML-259 (Fig. 5) is an inhibitor selective for CDK5
(IC50 = 64 nM) and CDK2 (IC50 = 98 nM). It is an ATP
competitive CDK inhibitor discovered by molecular model-
ing studies (Helal et al. 2004). Although it deWnitely needs
further validations and preclinical studies, this compound is
already available commercially. So far, no clinical study
has been reported for this agent.
SU 9516 (Fig. 5) is an inhibitor selective for CDK2
(IC50 = 0.022 M) and CDK1 (IC50 = 0.04 M), but less
selective toward CDK4 (IC50 ¸ 10 M). At higher concen-
trations, it can also inhibit PKC (IC50 ¸ 10 M), p38
(IC50 ¸ 10 M), PDGFR (IC50 ¸ 18 M) and EGFR
(IC50 ¸ 100 M). It was identiWed by the means of high-
throughput screening with CDK2 and tested on colon can-
cer cell line in which it decreased cell cycle progression and
induced apoptosis (Lane et al. 2001). So far, it has been
only tested in preclinical studies.
PD-0332991 (Fig. 6) is a highly speciWc inhibitor of
CDK4 (IC50 = 0.011 M) and CDK6 (IC50 = 0.016 M),
having no activity against a panel of 36 additional protein
kinases (Fry et al. 2004). It was an eVective antiprolifera-
tive agent against retinoblastoma-positive tumor cells,
inducing G1 arrest and reducing the phosphorylation of the
Rb protein. Administration of PD-0332991 reduces tumors
in mice bearing the Colo-205 human colon carcinoma. Sev-
eral phase I/II clinical studies with PD 0332991 have been
initiated, such as: a study in patients with advanced solid
tumors (excluding SCLC and retinoblastoma) or follicular
and diVuse large-cell non-Hodgkin’s lymphoma, phase I
Trial of PD-0332991 plus bortezomib in patients with
relapsed mantle cell lymphoma, phase 1 trial of
PD0332991 and paclitaxel in patients with Rb-expressing
advanced breast cancer, phase II study of PD 0332991 in
patients with recurrent Rb positive glioblastoma; however,
the results are not ready yet. Another phase I study of
sequential combination of PD-0032991 with bortezomib
and dexamethasone had been performed in 21 relapsed and
refractory multiple myeloma patients (Niesvizky et al.
2010). The most common treatment-related DAEs were
thrombocytopenia and neutropenia. One patient achieved a
very good partial response, 1 achieved a partial response,
and 3 had stable disease for more than 3 months. Very good
partial response was in a patient who had relapsed on lena-
lidomide, bortezomib and carWlzomib therapies as well as
on stem cell transplant. The phase II portion of the trial to
evaluate the antitumor activity of PD 0332991 is ongoing.
Yet another phase I study of the combination of PD
0332991 and letrozole for Wrst-line treatment of patients
with ER-positive, HER2-negative breast cancer had been
performed in 12 patients (Slamon et al. 2010). Most com-
mon DAEs included neutropenia, leucopenia and fatigue.
Three patients had partial response and 9 patients had stable
disease. A randomized phase II study has been initiated.
Fig. 5 Purvalanol A, BML-259 and SU 9516
Fig. 6 PD 0332991 and P276-00
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P276–00 (Fig. 6) is a highly speciWc inhibitor of CDK2
(IC50 = 10 nM), which is much less selective toward CDK1
(IC50 = 110 nM) and CDK4 (IC50 = 130 nM), with no sig-
niWcant activity toward 12 other kinases tested (IC50 =
2 M). It showed potent antiproliferative eVects against
various human cancer cell lines, such as MCF-7 and H-460
(Joshi et al. 2007). Several phase I/II clinical studies with
P279-00 have been initiated, such as an open-label, multi-
center phase I/II study of selective cyclin-dependent kinase
inhibitor P276-00 in combination with radiation in subjects
with recurrent and/or locally advanced squamous cell carci-
noma of head and neck and a phase I/II study to evaluate
safety and eYcacy of P276-00 in combination with gemcit-
abine in patients with pancreatic cancer. The results of
these studies are still in progress. Another phase I study in
patients with refractory neoplasms was performed. Major
DAEs were fatigue, hypotension, nausea, sweating and dry
mouth. No responses were observed (Hirte et al. 2007).
Conclusions
The Weld of CDK inhibitor development had seen a signiW-
cant enthusiasm and optimism in the past couple of
decades. Recent developments in the small-molecule CDK
inhibitor Weld led to several marketed products with a
diVerent spectrum of the inhibited targets. Actually, there
are many more CDK inhibitors developed than are
described in this review. Many more are still in develop-
ment. These developments provided the investigators,
interested in the role of CDKs in cancer or other cellular
processes, with a whole panel of tools. The variety of these
inhibitors allows us to choose the most eVective and rele-
vant approaches suited for the particular experiments. How
to choose the appropriate inhibitor? First of all, most of the
researchers would be limited by the availability of the com-
pounds. However, there are quite a number of commer-
cially inhibitors to choose from. Secondly, the investigator
has to choose the speciWcity of the inhibitor, according to
the CDK (or several CDKs) he would like to inhibit. Wish-
ful thinking, like “roscovitine is selective CDK5 inhibitor”,
will certainly not help in this decision. Lastly, if working on
a disease model, it would certainly help to consider using
the inhibitors, which are already under the investigation in
clinical trials. In some cases, if not most cases, the results
obtained using CDK inhibitors should be validated using
other techniques, such as siRNA,/micro-RNA knockdowns,
dominant-negative CDKs or knockout mice.
The basic as well as preclinical cancer research is not the
only Welds, which can proWt from the use of CDK inhibi-
tors. They continue to hold much potential as new agents in
the treatment of cancer. The crucial question that remains
unanswered is which CDK or range of CDKs should be tar-
geted. Studies with the inhibitors should determine whether
highly selective or rather broad-range CDK inhibitors are
more eVective for anticancer therapy. The therapeutic sig-
niWcance of inhibiting particular CDKs is greatly dependent
on the genetic background and the speciWc signaling path-
ways that direct proliferation of the tumor cells. Preclinical
studies in suitable animal models ought to provide impor-
tant information for the design of more clinical studies
assessing improved eYcacy of these agents. The results
from clinical studies to date imply that monotherapy might
not be the best application of CDK inhibitors. However, the
results of these agents in combination with chemotherapy
seem to be more optimistic. On the other hand, there is also
the lack of clinically useful prognostic and predictive bio-
markers that associate directly with CDK inhibition. In
addition, new insights into CDK biology will provide inno-
vative biomedical rationales for the therapeutic applica-
tions.
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